NCT05187182 2026-03-18
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Phase 1 Recruiting
Clinical Trials
14 trialsNCT04757363 2026-03-04
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT07223424 2025-11-10
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07152678 2025-09-03
BRIGHT-ESCC
National Taiwan University Hospital
Phase 2 Recruiting
NCT03044613 2025-03-06
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT05491616 2025-02-13
SANO-3
Erasmus Medical Center
Phase 2 Active not recruiting
NCT04984733 2023-11-29
ELEVATE
University of Southampton
Phase 2 Recruiting
NCT03544736 2023-03-22
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
Oslo University Hospital
Phase 1/2 Active not recruiting
NCT03416244 2022-09-29
RAMONA
AIO-Studien-gGmbH
Phase 2 Completed
NCT03409848 2022-05-18
INTEGA
AIO-Studien-gGmbH
Phase 2 Completed
NCT04503967 2020-08-07
OASIS
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT02946671 2020-03-06
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Phase 1 Completed